

Resource Summary Report

Generated by [NIF](#) on Jul 30, 2026

pcDNA3.3_CoV1_D28

RRID:Addgene_170447

Type: Plasmid

Proper Citation

RRID:Addgene_170447

Plasmid Information

URL: <http://www.addgene.org/170447>

Proper Citation: RRID:Addgene_170447

Insert Name: SARS-CoV-1 spike D28

Organism: SARS-CoV-1

Bacterial Resistance: Ampicillin

Defining Citation: [PMID:32540903](#)

Vector Backbone Description: Backbone Size:5500; Vector Backbone:pcDNA3.3; Vector Types:Mammalian Expression; Bacterial Resistance:Ampicillin

Plasmid Name: pcDNA3.3_CoV1_D28

Relevant Mutation: last 28aa deletion in c-terminal tail

Record Creation Time: 20220422T221952+0000

Record Last Update: 20260725T074237+0000

Ratings and Alerts

No rating or validation information has been found for pcDNA3.3_CoV1_D28.

No alerts have been found for pcDNA3.3_CoV1_D28.

Data and Source Information

Source: [Addgene](#)

Usage and Citation Metrics

We found 11 mentions in open access literature.

Listed below are recent publications. The full list is available at [NIF](#) .

Gonzales J, et al. (2025) Development of an ultrahigh affinity, trimeric ACE2 biologic as a universal SARS-CoV-2 antagonist. *Communications biology*, 8(1), 1428.

Sheward DJ, et al. (2024) Structural basis of broad SARS-CoV-2 cross-neutralization by affinity-matured public antibodies. *Cell reports. Medicine*, 5(6), 101577.

Paciello I, et al. (2024) Antigenic sin and multiple breakthrough infections drive converging evolution of COVID-19 neutralizing responses. *Cell reports*, 43(9), 114645.

Zoepfl M, et al. (2023) Antiviral activity of marine sulfated glycans against pathogenic human coronaviruses. *Scientific reports*, 13(1), 4804.

Dacon C, et al. (2023) Rare, convergent antibodies targeting the stem helix broadly neutralize diverse betacoronaviruses. *Cell host & microbe*, 31(1), 97.

Andreano E, et al. (2023) B cell analyses after SARS-CoV-2 mRNA third vaccination reveals a hybrid immunity like antibody response. *Nature communications*, 14(1), 53.

Fang Y, et al. (2022) An antibody that neutralizes SARS-CoV-1 and SARS-CoV-2 by binding to a conserved spike epitope outside the receptor binding motif. *Science immunology*, 7(76), eabp9962.

Andreano E, et al. (2022) Anatomy of Omicron BA.1 and BA.2 neutralizing antibodies in COVID-19 mRNA vaccinees. *Nature communications*, 13(1), 3375.

Song J, et al. (2022) LRRC15 inhibits SARS-CoV-2 cellular entry in trans. *PLoS biology*, 20(10), e3001805.

Hanke L, et al. (2022) Multivariate mining of an alpaca immune repertoire identifies potent cross-neutralizing SARS-CoV-2 nanobodies. *Science advances*, 8(12), eabm0220.

Song J, et al. (2021) LRRC15 is an inhibitory receptor blocking SARS-CoV-2 spike-mediated entry in trans. *bioRxiv : the preprint server for biology*.